- Shuffle
Toggle OnToggle Off
- Alphabetize
Toggle OnToggle Off
- Front First
Toggle OnToggle Off
- Both Sides
Toggle OnToggle Off
Front
How to study your flashcards.
Right/Left arrow keys: Navigate between flashcards.right arrow keyleft arrow key
Up/Down arrow keys: Flip the card between the front and back.down keyup key
H key: Show hint (3rd side).h key
PLAY BUTTON
PLAY BUTTON
30 Cards in this Set
- Front
- Back
|
disease-modifying antirheumatic drugs
|
methotrexate
sulfasalazine cyclosporine infliximab etanercept gold salts leflunomide penicillamine cyclophosphamide azathioprine mycophenolate mofetil |
|
DOC for rheumatoid arthritis
|
methotrexate
|
|
this antirheumatic drug is cytotoxic to rapidly dividing immune cells due to inhibition of dihydrofolate reductase
|
methotrexate
|
|
this antirheumatic drug is metabolized to 6-mercaptopurine which suppresses de novo purine synthesis
|
azathioprine
|
|
adverse effects associated with methotrexate
|
mucosal ulcers
hepatotoxicity |
|
Against rheumatoid arthritis, it operates by inhibiting lymphocyte proliferation, phospholipase A2, antigen presentation in dendritic cells, release of enzymes from lysosomes, release of reactive oxygen species from macrophages, and production of IL-1.
|
chloroquine
|
|
adverse effects associated with chloroquine
|
retinal damage
GI disturbances nightmares |
|
this antirheumatic drug alters the morphology and function of macrophages and inhibits IL-8
|
gold salts
|
|
adverse effects of this antirheumatic drug include gray-blue pigmentation of skin, renal damage, and thrombocytopenia
|
gold salts
|
|
this antirheumatic drug inhibits calcineurin
|
cyclosporine
|
|
this antirheumatic drug is a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH) in purine biosynthesis (specifically guanine synthesis) which is necessary for the growth of T cells and B cells.
|
mycophenolate mofetil
|
|
adverse effects associated with mycophenolate mofetil
|
bone marrow suppression
hepatotoxicity |
|
adverse effects associate with cyclosporine
|
nephrotoxicity
hepatotoxicity HTN |
|
this antirheumatic drug is also a monoclonal antibody against TNF-a
|
infliximab
|
|
this antirheumatic drug is a recombinant human receptor of TNF-a
|
etanercept
|
|
this two antirheymatic drugs are associated with latent TB reactivation
|
infliximab
etanercept |
|
this antirheumatic drug crosslinks DNA and prevents replication
|
cyclophosphamide
|
|
adverse effects associated with cyclophosphamide
|
hemorrhagic cystitis
bladder transitional cell carcinoma |
|
this antirheumatic drug inhibits IgA/IgM rheumatic factor production and reduces rate of new joint damage
|
sulfasalazine
|
|
this gout drug binds and stabilizes tubulin and inhibits mitotic spindle formation and polymerization impairing leukocyte chemotaxis
|
colchicine
|
|
irreversible inhibitor of xanthine oxidase
|
allopurinol
|
|
inhibits reabsorption of uric acid in PCT of kidneys
|
probenecid
|
|
chelating agent used for rheumatoid arthritis
|
penicillamine
|
|
adverse effects associated with colchicine
|
diarrhea
severe liver and kidney damage in overdose |
|
adverse effects associated with probenecid
|
exacerbation of acute gout
inhibits renal tubular secretion of weak acids such as penicillin |
|
nonpurine reversible inhibitor of xanthine oxidase that doesn't inhibit other enzymes in purine and pyrimidine metabolism
|
febuxostate
|
|
adverse effects associated with allpurinol
|
hypersensitivity reaction
bone marrow suppression |
|
antirheumatic drug that inhibits mitochondrial enzyme dihydroorotate dehydrogenase (an enzyme involved in de novo pyrimidine synthesis)
|
leflunomide
|
|
adverse effects of leflunomide
|
liver damage
myelosuprresion don't get pregnant |
|
binds to the CD11a subunit of lymphocyte function-associated antigen 1 and acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out of blood vessels into tissues
|
Efalizumab
|
